Millions could benefit from bipolar breakthrough

December 3rd, 2018

Breakthrough in bipolar disorder treatment could change lives of millions

The lives of millions of bipolar sufferers around the world are about to change forever as The London Psychiatry Centre announced in Cape Town a brand-new discovery in the treatment of the crippling illness. The treatment is now available at Newcastle Premier Health.

On Sunday the 2nd December; representatives from our clinic partner, The London Psychiatry Centre, addressed a globally represented delegation at the 18th International Congress of Endocrinology conference. They unveiled the discovery and findings from 20 jaw-dropping cases treated at the Centre where patients had taken part in the new life-changing treatment of bipolar disorders which is available form Newcastle Premier Health.

The new breakthrough applies a concept known as ‘precision medicine’ to effectively predict and target the treatment of patients based on their genetic profile. The process uses a combination of rTMS (Repetitive Transcranial Magnetic Stimulation) and high dose thyroid hormone, alongside targeted genetic testing for thyroid activating enzymes, which ensures the patient suffers minimal, if any side effects.

The use of precision medicine has led to a ground-breaking discovery which could signal a worldwide change in how millions of bipolar disorder sufferers are medically treated in the future.

Dr Andy Zamar (Consultant Psychiatrist), Dr Abbi Lulsegged (Consultant Endocrinologist), Dr Robin Roberts (Consultant Cardiologist) and their team at The London Psychiatry Centre have found through genetic testing that over 90% of the bipolar cases randomly and consecutively tested have a deficiency of one, two or both enzymes needed to activate thyroid hormone in the brain and the body.

“We believe we have cracked it!” said Consultant Psychiatrist, Dr Andy Zamar of The London Psychiatry Centre.

The London Psychiatry Centre pioneered the effective combination of rTMS and high dose thyroid hormone to specifically target in those sufferers who lack the activating enzymes Deiodinase 1 and Deiodinase 2. These patients are unable to activate normal doses of thyroid hormone. The team found that as a result, they can be treated with minimal or no side effects with high dose thyroxine and rTMS, and some may need one additional drug as opposed to the usual requirement of a standard of 3 to 4 drugs which, as a rule, cause significant side effects.

Patients who had the combination of rTMS and high dose thyroid combination saw their condition recover fully after years of unsuccessful treatment with drugs*. This effective new process also displays generally a lack of or minimal side effects, which is wonderful news for patients receiving the treatment.

The fact these patients did not suffer side effects on High dose Thyroxine has been previously reported but the reasons were never understood, and the treatment was never targeted to a specific identifiable population as this was never linked to Deiodinase enzyme deficiency.

Dr Zamar continues: “This game-changing discovery is the result of more than a decade of work involving the treatment of nearly 400 people with genetic tests carried out in over 100 of these patients. We hope our findings result in a global transformation of how millions of people are treated for this debilitating illness and signals a reduction in their required medication and side effects.”

Newcastle Premier Health is one of three clinics in the UK operating the service in partnership with The London Psychiatry Centre. The other two clinics are in London.

For further information about the work of London Psychiatry Centre and the service available to people in the North East, please click here.

*Highlighted in a Care Quality Commission Report – The London Psychiatry Centre 2017